Scott Goeken

Company: Corbus Pharmaceuticals

Job title: General Counsel

Seminars:

Charting the Course of Lenabasum: A Case Study in CB2 Drug Development & Regulatory Strategy 11:00 am

DEA scheduling challenges: Managing regulatory hurdles and delays tied to schedule I/ II status, including DEA registration and supply chain restrictions HAL study requirements: Conducting human abuse liability studies despite low CB2- related CNS activity, as mandated by the FDA Cost burden on development of schedule I/II Trials: High financial and operational costs due to…Read more

day: Conference Day Two